A recent study suggests that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide may regain lost weight much more quickly than those who stop traditional lifestyle plans.
Published data in a prominent health publication points out that while obese people frequently drop substantial amounts of their body weight while undergoing treatment, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals buying these treatments must be aware of the potential of quick weight regain when the treatment ends," warns researcher Dr. Susan Jebb.
This pace of recovery means a return to original weight in about 18 months.
Weighing Therapies
The analysis, which reviewed dozens of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with conventional dieting.
The team emphasize that individuals who lose weight through diet and exercise usually see a more gradual weight regain—perhaps 0.1 kg a month—after stopping.
The Reason for the Quick Rebound
Experts propose the way of the injections explains the heightened weight return.
The injections mimic a natural hormone called GLP-1, which controls hunger.
"Long-term administration of the hormone concentrations far above than normal could lead to the system to generate a reduced amount of its own natural GLP-1, and could lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement leads to hunger is unsuppressed, making binge eating much more probable."
An Ongoing Disease?
Medical guidelines suggest the jabs for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.
Many experts argue that, given the likelihood of weight regain, the treatment should be considered life-long.
This view is echoed by drug manufacturers, who state that the results "underscore the chronic character of excess weight," comparing it to managing conditions like hypertension.
Patient Experiences
People who have discontinued the jabs describe a intense resurgence of appetite.
"It was like a switch activating and you're instantly starving," recalled one woman.
This difficulty is worsened if individuals have not established lasting dietary or behavioural modifications during treatment.
Widespread Adoption
Survey data indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with interest remaining high.
- Use is higher among women compared to males.
- The middle-aged age group shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
Finally, clinicians caution that while the jabs are potent agents for shedding pounds, they are not a permanent cure and long-term success likely depends on combined lifestyle changes.
